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Background: The role of CYP2C19*2 polymorphism in clopidogrel response and cardiovascular prognosis has come under question in recent 
studies. Measurement of endothelial function and arterial stiffness are well validated in large population studies as strong predictors of adverse 
cardiovascular outcomes. We examined the impact of CYP2C19*2 polymorphism on endothelial function and arterial stiffness in coronary artery 
disease (CAD) patients.
Methods: The study included 245 patients with stable CAD, receiving clopidogrel regimen (75mg/d). CYP2C19*2 genotyping was performed by 
real-time polymerase chain reaction. CAD patients were divided in two groups. Group A consisted of patients homozygous for the wild type and group 
B consisted of patients carrying at least one CYP2C19*2 loss-of-function allele. Endothelial function was evaluated by flow-mediated dilatation 
(FMD). Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic stiffness.
Results: Group A included 153 patients (62.4%) and group B 92 patients (37.6%). There was no statistically significant difference between the two 
groups in age (62±10 vs. 60±12 years, p=0.12), male sex (90% vs. 91%, p=0.65) and the presence of dyslipidemia (74% vs. 70%, p=0.57), diabetes 
mellitus (27% vs. 27%, p=0.97) and arterial hypertension (80% vs. 81%, p=0.74). Importantly, there was no difference in FMD (4.82±2.17% vs. 
4.92±2.47%, p=0.74) and PWV values (9.08±2.02m/sec vs. 8.89±2.49m/sec, p=0.55) between the two groups.
Conclusion: CYP2C19*2 polymorphism is not associated with endothelial function and arterial stiffness in CAD patients receiving clopidogrel. 
These findings are consisted with recent large trials, which document the absence of an effect of the CYP2C19*2 loss-of-function alleles on 
cardiovascular risk, among CAD patients treated with clopidogrel.
